MAPS_2A: MAPS, figure 2A

MAPS_2AR Documentation

MAPS, figure 2A

Description

Kaplan-Meier digitized data from MAPS, figure 2A (PMID 26719230). A reported sample size of 448 for a primary endpoint of OS in lung cancer.

Usage

MAPS_2A

Format

A data frame of 448 observations and 3 variables:

time event time (in months)
event OS event indicator (0: no event, 1: event)
arm treatment arms (pc, pcb)

Source

Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387: 1405–14.

Examples

summary(MAPS_2A)

kmplot(MAPS_2A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.